New Delhi: The shares of Samvardhana Motherson International and Alkem Laboratories are expected to be in news on May 30, 2025, Friday as both the companies declared their Q4 2024-25 Results on Thursday.
Alkem Laboratories Q4 net profit rose 6 percent to Rs 322 crore, while Samvardhana Motherson’s January-March quarter profit went up 19 per cent at Rs 1,050 crore.
Samvardhana Motherson International shares on Thursday ended 2.29 per cent up at Rs 152.15 apiece on BSE. Alkem Laboratories shares closed at Rs 5,325 apiece.
Samvardhana Motherson Q4 2024-25 Results
Samvardhana Motherson International shares are expected to be in news today as the auto components maker declared its Q4 Results of 2024-25. The company’s consolidated profit after tax surged 19 per cent to Rs 1,050 crore in the January-March quarter of FY25, while it had posted a PAT of Rs 879 crore for the same period in 2023-24 fiscal.
In a regulatory filing, Samvardhana Motherson’s total revenue from operations increased to Rs 29,317 crore from Rs 27,666 crore a year ago.
For full fiscal FY25, the company recorded a consolidated PAT of Rs 3,803 crore, while it was Rs 2,716 crore in 2023-24. Revenue increased to Rs 1,13,663 crore from Rs 98,692 crore.
“Our performance demonstrates the resilience and adaptability of our business. Leveraging our strong engineering and manufacturing expertise, we are well-equipped to meet our customers’ needs, positioning us for long-term sustainable growth,” Motherson Chairman Vivek Chaand Sehgal said.
Alkem Laboratories Q4 Results 2024-25
In its Q4 Results 2024-25, Alkem Laboratories mentioned that its consolidated net profit increased 6 per cent to Rs 322 crore as compared to a net profit of Rs 304 crore in the last quarter of 2023-24 fiscal.
The company’s revenue from operations went up to Rs 3,144 crore in January-March quarter of FY25 as against Rs 2,936 crore in the year-ago period.
In a regulatory filing, the company’s consolidated net profit stood at Rs 2,215 crore in 2024-25, while it was Rs 1,811 crore in FY24. Revenue increased to Rs 12,964 crore in FY25 as against Rs 12,667 crore in 2023-24 fiscal.
“Our domestic business continues to gain momentum, reinforcing our confidence in its long-term growth trajectory. This performance is driven by strong execution and targeted initiatives across our domestic operations,” Alkem CEO Vikas Gupta said.
“As we moved forward, we remain focused on strategic growth opportunities and operational excellence to drive sustainable returns,” Gupta said.
The company informed that its board gave a green signal for a final dividend of Rs 8 per share of Rs 2 each for the financial year ended March 31, 2025.